EGFR and non-small cell lung carcinoma: Importantly, they screened three different cohorts of patients (treatment-naïve patients with EGFR+ NSCLC treated with either EGFRTKI and/or MET inhibitors), and they found that ‘acquired’ MET mutations are extremely rare in treatment-naïve patients (0.06%) and have higher frequency after EGFR/MET-Is [103].